AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Total Non-current Assets
All assets not expected to be converted to cash within one year.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Total Non-current Assets · Q3 FY2025 · quarter ended Sep 2025
Total non-current assets of €32.62M in Q3 FY2025
Q3 FY2025 total non-current assets was €32.62M.
Context
- Total non-current assets amounted to 19.7% of total assets at the end of Q3 FY2025.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
Currency unavailable · from the balance sheet
No Total Non-current Assets data reported for this period type.
Total Non-current Assets vs competitors
How AGMB compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Total non-current assets amounts to 19.7% of total assets for AGMB, versus a peer median of 6.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $88.49M USD | -0.9% | -26.6% | 44.5% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $46.53M USD | -50.2% | +155.6% | 8.3% |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €32.62M EUR | — | — | 19.7% |
| Mar 2026 | $13.58M USD | -77.0% | -55.7% | 4.1% | |
| Mar 2026 | $808K USD | +57.5% | -26.9% | 1.3% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | -25.5% | -26.8% | 6.2% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.